On April 2, 2014, the U.S. International Trade Commission issued a press release announcing their vote to institute an investigation ofCertain Hemostatic Products and Components Thereof (Inv. No. 337-TA-913).

The investigation is based on a February 28, 2014 complaint and a March 19, 2014 letter supplementing the complaint filed by Baxter International Inc. of Deerfield, Illinois, Baxter Healthcare Corp. of Deerfield, Illinois, and Baxter Healthcare SA of Switzerland alleging violation of Section 337 in the importation into the U.S. and sale of certain hemostatic products and components thereof that infringe one or more claims of U.S. Patent Nos. 8,303,981; 8,512,729; 6,066,325; 8,357,378; and 8,603,511.  See our March 5, 2014 post for more details.

According to the Notice of Investigation, the Commission has identified Johnson & Johnson Inc. of Brunswick, New Jersey, Ethicon, Inc. of Somerville, New Jersey, Ferrosan Medical Devices A/S of Denmark, and Packaging Coordinators, Inc. of Philadelphia, Pennsylvania as the respondents in this investigation.

Lastly, Chief ALJ Charles E. Bullock issued a notice indicating that he will be the presiding Administrative Law Judge in this investigation.